PIK3CA and neoplasm: Interestingly, the detection of a PIK3CA mutation in circulating tumor DNA in MBC patients treated with alpelisib was linked to significantly improved progression-free survival under treatment, suggesting a context-dependent activation of PI3K in metastatic processes [19].